Education
About Us
Working with TipRanks
Follow Us
Traws Pharma (TRAW)
NASDAQ:TRAW
TRAW Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.02 - $26.20
Previous CloseN/A
Volume35.69K
Average Volume (3M)103.28K
Market Cap
$12.08M
Enterprise Value$243.80K
Total Cash (Recent Filing)$55.07M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Apr 01, 2025EPS Estimate
-9.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-141.34
Shares Outstanding5,033,290
10 Day Avg. Volume46,914
30 Day Avg. Volume103,285
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)38.02
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.16
Enterprise Value/Ebitda-0.01
Forecast
1Y Price Target
$6.00Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Traws Pharma News
PremiumCompany Announcements
Traws Pharma Announces CEO Transition and Investor Update
PremiumCompany Announcements
Traws Pharma Regains Nasdaq Compliance with $20M Financing
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TRAW FAQ
What was Traws Pharma’s price range in the past 12 months?
Traws Pharma lowest stock price was $2.02 and its highest was $26.20 in the past 12 months.
What is Traws Pharma’s market cap?
Traws Pharma’s market cap is $12.08M.
When is Traws Pharma’s upcoming earnings report date?
Traws Pharma’s upcoming earnings report date is Apr 01, 2025 which is tomorrow.
How were Traws Pharma’s earnings last quarter?
Traws Pharma released its earnings results on Nov 14, 2024. The company reported -$8.81 earnings per share for the quarter, missing the consensus estimate of -$6.25 by -$2.56.
Is Traws Pharma overvalued?
According to Wall Street analysts Traws Pharma’s price is currently Undervalued.
Does Traws Pharma pay dividends?
Traws Pharma does not currently pay dividends.
What is Traws Pharma’s EPS estimate?
Traws Pharma’s EPS estimate is -9.55.
How many shares outstanding does Traws Pharma have?
Traws Pharma has 5,033,290 shares outstanding.
What happened to Traws Pharma’s price movement after its last earnings report?
Traws Pharma reported an EPS of -$8.81 in its last earnings report, missing expectations of -$6.25. Following the earnings report the stock price went down -10.573%.
Which hedge fund is a major shareholder of Traws Pharma?
Currently, no hedge funds are holding shares in TRAW
---
Traws Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (150.00% Upside)
$6.00 (150.00% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.49%
12-Months-Change
Fundamentals
Return on Equity
-2255.45%
Trailing 12-Months
Asset Growth
-66.95%
Trailing 12-Months
Company Description
Traws Pharma
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
---
TRAW Stock 12 Month Forecast
Average Price Target
$6.00
▲(150.00% Upside)
Technical Analysis
Best Analysts Covering TRAW
1 Year
1 Year Success Rate
2/18 ratings generated profit
1 Year Average Return
-42.88%
reiterated a buy rating 4 months ago
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -42.88% per trade.
---